JGC
DERM icon

J. Goldman & Co’s Journey Medical DERM Stock Holding History

J. Goldman & Co’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$974K Sell
137,584
-362,604
-72% -$2.07M 0.03% 468
2026
Q1 		$2.35M Sell
500,188
-298,178
-37% -$2.31M 0.07% 297
2025
Q4 		$6.16M Buy
+798,366
New +$6.26M 0.16% 170

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

J. Goldman & Co's DERM Position: Q2 2026 in Review

J. Goldman & Co reduced its Journey Medical (DERM) stake by 72% in Q2 2026, selling an estimated $2.07M and leaving 137,584 shares worth $974K. The position accounts for 0.03% of the portfolio, ranked #468.

J. Goldman & Co first reported a position in DERM in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.16M in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • J. Goldman & Co held 137,584 shares of Journey Medical worth $974K as of Q2 2026.
  • J. Goldman & Co sold 362,604 Journey Medical shares in Q2 2026, an estimated $2.07M.
  • Journey Medical made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #468 holding.
  • J. Goldman & Co first reported a position in Journey Medical in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Journey Medical position peaked at $6.16M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.